You are here: Home » PTI Stories » National » News
Business Standard

Zydus Cadila gets USFDA nod for antipsychotic drug

Press Trust of India  |  New Delhi 

Tuesday said it has received final approval from the US health regulator to market drug tablets.

has received the approval from the Food and Drug Administration (USFDA) to market the drug in the strengths of 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, the company said in a BSE filing.

said the drug will be produced at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

Aripiprazole, an drug (atypical type), is used to treat such as bipolar disorder, schizophrenia, Tourette's disorder, and irritability associated with

It is also used in combination with other medications to treat It works by helping restore the balance of certain in the brain (neurotransmitters)

The group has more than 243 approvals, and so far filed over 330 abbreviated new drug applications (ANDAs) since it started filings in 2003-04.

Shares of Cadila Healthcare, the listed entity of the group, were trading 0.08 per cent lower at Rs 347.90 apiece on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, January 08 2019. 12:30 IST